1|Page
NUR-641E FINAL EXAM PREP | ALL POSSIBLE
QUESTIONS AND ANSWERS | UPDATES | 100%
CORRECT GCU
1. A patient with chronic kidney disease is prescribed a medication that
is primarily eliminated unchanged through the kidneys. The patient's
renal function has declined substantially since the medication was
initiated. Which pharmacokinetic change should the nurse anticipate?
A. Increased renal clearance and shortened half-life
B. Decreased renal clearance with potential drug accumulation and
prolonged half-life
C. Increased hepatic first-pass metabolism
D. Decreased drug distribution into tissues
Answer: B
Rationale: Reduced renal function decreases elimination of renally
cleared medications, potentially increasing serum concentrations and
prolonging the drug's half-life.
2. A medication has a half-life of 12 hours and is administered
repeatedly at regular intervals. Approximately how long would the nurse
expect it to take for the medication to approach steady-state
concentration?
A. 6 hours
B. 12 hours
C. 24 hours
D. Approximately 48–60 hours
Answer: D
Rationale: Most medications approach steady state after approximately
four to five half-lives. For a 12-hour half-life, this corresponds to
roughly 48–60 hours.
,2|Page
3. A patient receives a medication intravenously rather than orally.
Which pharmacokinetic characteristic explains why intravenous
administration produces 100% bioavailability?
A. The medication undergoes extensive hepatic metabolism before
reaching circulation.
B. The medication is absorbed more slowly through the gastrointestinal
tract.
C. The medication is delivered directly into systemic circulation,
bypassing the absorption process.
D. The medication is more highly protein bound.
Answer: C
Rationale: Intravenous administration delivers the medication directly
into the bloodstream, resulting in complete systemic availability.
4. A patient is prescribed a medication that is highly protein bound. The
patient subsequently develops severe hypoalbuminemia. Which effect is
most clinically important?
A. A larger fraction of the medication may remain unbound and
pharmacologically active.
B. The medication will automatically become completely inactive.
C. Renal filtration will always decrease to zero.
D. Gastrointestinal absorption will be completely eliminated.
Answer: A
Rationale: Reduced albumin can increase the unbound fraction of
highly protein-bound medications, potentially increasing pharmacologic
effects and toxicity.
5. A patient taking warfarin begins treatment with another medication
that inhibits the hepatic enzyme responsible for warfarin metabolism.
Which outcome should the nurse anticipate?
,3|Page
A. Decreased warfarin concentration and reduced anticoagulation
B. Increased warfarin concentration with a greater risk of bleeding
C. Immediate renal elimination of warfarin
D. Complete prevention of thrombus formation
Answer: B
Rationale: Enzyme inhibition can reduce warfarin metabolism,
increasing serum drug concentration and potentially increasing INR and
bleeding risk.
6. A patient taking a medication metabolized by CYP3A4 is prescribed a
strong CYP3A4 inducer. What pharmacokinetic effect is most likely?
A. Decreased metabolism of the medication
B. Increased metabolism that may reduce the medication's therapeutic
concentration
C. Complete prevention of renal elimination
D. Increased bioavailability through intravenous administration
Answer: B
Rationale: Enzyme induction increases metabolic activity and may
lower concentrations of medications that are CYP3A4 substrates.
7. A patient with heart failure is prescribed an ACE inhibitor. Which
laboratory values are particularly important to monitor after initiation or
dose escalation?
A. Potassium and serum creatinine
B. Hemoglobin and platelet count only
C. Calcium and magnesium only
D. Amylase and lipase
Answer: A
Rationale: ACE inhibitors can increase potassium levels and may alter
renal function, making serum potassium and creatinine important
monitoring parameters.
, 4|Page
8. A patient taking an ACE inhibitor develops facial swelling, tongue
swelling, and difficulty breathing. Which action should the nurse
prioritize?
A. Administer the next scheduled dose.
B. Recognize possible angioedema and initiate emergency management
of the airway.
C. Encourage oral fluids.
D. Reassure the patient that the reaction is expected.
Answer: B
Rationale: ACE-inhibitor-associated angioedema can rapidly
compromise the airway and requires immediate evaluation and
intervention.
9. A patient with heart failure is prescribed sacubitril/valsartan. Which
teaching point is particularly important?
A. The patient should take an ACE inhibitor simultaneously unless
instructed otherwise.
B. The medication can contribute to hypotension, renal impairment, and
hyperkalemia, requiring appropriate monitoring.
C. Serum potassium never needs monitoring.
D. The medication is used only for acute bacterial infections.
Answer: B
Rationale: Sacubitril/valsartan can cause hypotension, renal
dysfunction, and hyperkalemia. ACE inhibitors require an appropriate
washout period before initiation because of angioedema risk.
10. A patient with atrial fibrillation is prescribed a direct oral
anticoagulant. Which clinical assessment is most important when
evaluating the safety of therapy?
A. Assessment for bleeding and appropriate renal function
B. Assessment of visual acuity only
NUR-641E FINAL EXAM PREP | ALL POSSIBLE
QUESTIONS AND ANSWERS | UPDATES | 100%
CORRECT GCU
1. A patient with chronic kidney disease is prescribed a medication that
is primarily eliminated unchanged through the kidneys. The patient's
renal function has declined substantially since the medication was
initiated. Which pharmacokinetic change should the nurse anticipate?
A. Increased renal clearance and shortened half-life
B. Decreased renal clearance with potential drug accumulation and
prolonged half-life
C. Increased hepatic first-pass metabolism
D. Decreased drug distribution into tissues
Answer: B
Rationale: Reduced renal function decreases elimination of renally
cleared medications, potentially increasing serum concentrations and
prolonging the drug's half-life.
2. A medication has a half-life of 12 hours and is administered
repeatedly at regular intervals. Approximately how long would the nurse
expect it to take for the medication to approach steady-state
concentration?
A. 6 hours
B. 12 hours
C. 24 hours
D. Approximately 48–60 hours
Answer: D
Rationale: Most medications approach steady state after approximately
four to five half-lives. For a 12-hour half-life, this corresponds to
roughly 48–60 hours.
,2|Page
3. A patient receives a medication intravenously rather than orally.
Which pharmacokinetic characteristic explains why intravenous
administration produces 100% bioavailability?
A. The medication undergoes extensive hepatic metabolism before
reaching circulation.
B. The medication is absorbed more slowly through the gastrointestinal
tract.
C. The medication is delivered directly into systemic circulation,
bypassing the absorption process.
D. The medication is more highly protein bound.
Answer: C
Rationale: Intravenous administration delivers the medication directly
into the bloodstream, resulting in complete systemic availability.
4. A patient is prescribed a medication that is highly protein bound. The
patient subsequently develops severe hypoalbuminemia. Which effect is
most clinically important?
A. A larger fraction of the medication may remain unbound and
pharmacologically active.
B. The medication will automatically become completely inactive.
C. Renal filtration will always decrease to zero.
D. Gastrointestinal absorption will be completely eliminated.
Answer: A
Rationale: Reduced albumin can increase the unbound fraction of
highly protein-bound medications, potentially increasing pharmacologic
effects and toxicity.
5. A patient taking warfarin begins treatment with another medication
that inhibits the hepatic enzyme responsible for warfarin metabolism.
Which outcome should the nurse anticipate?
,3|Page
A. Decreased warfarin concentration and reduced anticoagulation
B. Increased warfarin concentration with a greater risk of bleeding
C. Immediate renal elimination of warfarin
D. Complete prevention of thrombus formation
Answer: B
Rationale: Enzyme inhibition can reduce warfarin metabolism,
increasing serum drug concentration and potentially increasing INR and
bleeding risk.
6. A patient taking a medication metabolized by CYP3A4 is prescribed a
strong CYP3A4 inducer. What pharmacokinetic effect is most likely?
A. Decreased metabolism of the medication
B. Increased metabolism that may reduce the medication's therapeutic
concentration
C. Complete prevention of renal elimination
D. Increased bioavailability through intravenous administration
Answer: B
Rationale: Enzyme induction increases metabolic activity and may
lower concentrations of medications that are CYP3A4 substrates.
7. A patient with heart failure is prescribed an ACE inhibitor. Which
laboratory values are particularly important to monitor after initiation or
dose escalation?
A. Potassium and serum creatinine
B. Hemoglobin and platelet count only
C. Calcium and magnesium only
D. Amylase and lipase
Answer: A
Rationale: ACE inhibitors can increase potassium levels and may alter
renal function, making serum potassium and creatinine important
monitoring parameters.
, 4|Page
8. A patient taking an ACE inhibitor develops facial swelling, tongue
swelling, and difficulty breathing. Which action should the nurse
prioritize?
A. Administer the next scheduled dose.
B. Recognize possible angioedema and initiate emergency management
of the airway.
C. Encourage oral fluids.
D. Reassure the patient that the reaction is expected.
Answer: B
Rationale: ACE-inhibitor-associated angioedema can rapidly
compromise the airway and requires immediate evaluation and
intervention.
9. A patient with heart failure is prescribed sacubitril/valsartan. Which
teaching point is particularly important?
A. The patient should take an ACE inhibitor simultaneously unless
instructed otherwise.
B. The medication can contribute to hypotension, renal impairment, and
hyperkalemia, requiring appropriate monitoring.
C. Serum potassium never needs monitoring.
D. The medication is used only for acute bacterial infections.
Answer: B
Rationale: Sacubitril/valsartan can cause hypotension, renal
dysfunction, and hyperkalemia. ACE inhibitors require an appropriate
washout period before initiation because of angioedema risk.
10. A patient with atrial fibrillation is prescribed a direct oral
anticoagulant. Which clinical assessment is most important when
evaluating the safety of therapy?
A. Assessment for bleeding and appropriate renal function
B. Assessment of visual acuity only
